Suzy Jones was previously Head of Business Development @ Genetech prior to it's aquisition by Roche for $45B in 2009, don't forget Genetech was a company twice the size of CSL.
So why would Suzy Jones previously the head of business development at a multi billion dollar pharmaceutical company come here? with a micro cap of $11M but a portfolio of novel human antibody treatments for cancer entering clinical trials & setting up to be outlicensed.
I highly doubt she came because the science sucked
Make up your own minds.
- Forums
- ASX - By Stock
- PAB
- the demise of csl
the demise of csl, page-8
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.6¢ | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.007 |
5 | 1215781 | 0.006 |
15 | 8550157 | 0.005 |
10 | 5864000 | 0.004 |
5 | 5899016 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.006 | 20000 | 1 |
0.007 | 1384808 | 3 |
0.008 | 2061233 | 5 |
0.010 | 1396000 | 6 |
0.011 | 680000 | 2 |
Last trade - 09.34am 28/08/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |
Day chart unavailable
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online